Tuesday - May 5, 2026
GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and Over Accepted for Review by China National Medical Products Administration
February 07, 2024
LONDON, England, Feb. 7 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Feb. 6, 2024:

GSK plc (LSE/NYSE: GSK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review the regulatory application of Shingrix (Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over at increased risk.

Recombina . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products